SHR-1210, a Novel Anti-PD-1 Antibody, in Combination With Anlotinib As Second-line or Above Treatment in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer: a Phase II Study
Latest Information Update: 17 Mar 2021
At a glance
- Drugs Camrelizumab (Primary) ; Catequentinib (Primary)
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 17 Mar 2021 New trial record